Abstract
The aim of the present study was to assess the effects of ipriflavone administration in the prevention of the rapid bone loss that follows ovariectomy in women. After 10–30 days from bilateral ovariectomy, patients received either the sole calcium supplementation (500 mg/day, n=16) or ipriflavone (600 mg/day, n=16) in addition to the same daily calcium supplement for 12 months. In calcium-treated subjects urinary hydroxyproline excretion, serum alkaline phosphatase and plasma bone Gla protein levels showed a substantial (p<0.01) increase, while radial bone density significantly (p<0.01) decreased 6 months after surgery. In ipriflavone treated group the patterns of biochemical markers indicated that ipriflavone can restrain the bone remodeling processes and radial bone density showed no significant modification during the 12 month study period. These results demonstrate that ipriflavone administration prevents the rapid bone loss that follows ovariectomy. Thus, ipriflavone can represent an actractive alternative for the prevention of osteoporosis in postmenopausal women who present contraindications to the estrogen replacement therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wallach S., Henneman P.H. Prolonged estrogen therapy in postmenopausal women. JAMA 171: 1637, 1959.
Lindsay R. Estrogen therapy in the prevention and management of osteoporosis. Am. J. Obstet. Gynecol. 156: 1347, 1987.
Gambrell R.D. The menopause: benefits and risks of estrogen-progestogen replacement therapy. Fertil. Steril. 37: 457, 1982.
Whitcroft S.U., Stevenson J.C. Hormone replacement therapy: risks and benefits. Clin. Endocrinol. (Oxf.) 36: 15, 1992.
Kuhnau J. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rey Nutr. Diet. 24: 112, 1976
Brandi M.L. Flavonoids: biochemical effects and therapeutic applications. Bone and Mineral 19 (Suppl.): S3, 1992.
Suda A. Effect of parathyroid hormone on parietal bones of rats and effect of ipriflavone. J. Bone Min. Metab. 5: 51, 1987.
Bonucci E., Ballanti P., Martelli A., Mereto E, Brambilla G., Bianco P., Bufalino L. Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats. Calcif. Tissue. Int. 50: 314, 1992.
Tsuda M., Kitazaki T., Ito T., Fujita T. The effects of ipriflavone (TC-80) on bone resorption in tissue colture. J. Bone Min. Res. 1: 207, 1986.
Benvenuti S., Tanini A., Frediani U., Bianchi S., Masi L., Casano R., Bufalino L., Serio M., Brandi M.L. Effects of ipriflavone and its metabolits on a clonal osteoblastic cell line. J. Bone Min. Res. 6: 987, 1991.
Shino A., Matsuo T., Tsuda M., Yamazaki I., Tsikuda R., Kitazaki T., Shiota K., Odaka H., Yoshida K. Effects of ipriflavone on bone and mineral metabolism in the streptozotocin diabetic rat. J. Bone Min. Metab. 3: 27, 1986.
Yamazaki I., Shino A., Tsukuda R. Effect of ipriflavone on osteoporosis induced by ovariectomy in rats. J. Bone Min. Metab. 3: 205, 1986.
Yamazaki I., Shino A., Shimizu Y., Tsukuda R., Shirakawa Y., Kinioshita M. Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats. Life Sci. 38: 951, 1986.
Melis G.B., Gambacciani M., Spinetti A., Paoletti A.M., Bufalino L., Cecchi G., Fioretti P. Lack of direct estrogenic effect of ipriflavone in postmenopausal women. In: Christiansen C. and Overgaard K. (Eds.), Osteoporosis 1990, Osteopress ApS, Copenaghen, 1990, p. 2174.
Newman R.E., Logan M.A. The determination of hydroxyproline. J. Biol. Chem. 184: 299, 1950.
Giordani R., Lucchetti A., Nicollini A., Fiochi U. La determinazione della idrossiprolina urinaria: confronta fra due metodi. Bollettino della Societá Medico-Chirurgica Pisana 4: 1, 1983.
Agnusdei D., Zacchei F., Bigazzi S., Cepollaro C., Nardi P., Montagnani M., Gennari C. Metabolic and clinic effects of ipriflavone in established postmenopausal osteoporosis. Drugs Exp. Clin. Res. 15: 97, 1989.
Agnusdei D., Camporeale A., Zacchei F., Gennari C., Baroni M.C., Costi D., Biondi M., Passeri M., Ciacca A., Sbrenna C., Falsettini E., Ventura A. Effects of ipriflavone on bone mass and bone remodeling in patients with established postmenopausal osteoporosis. Curr. Ther. Res. 51: 82, 1992.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gambacciani, M., Spinetti, A., Cappagli, B. et al. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J Endocrinol Invest 16, 333–337 (1993). https://doi.org/10.1007/BF03348848
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348848